logo
Impossible Foods aims to put plant-based burgers on European menus this year

Impossible Foods aims to put plant-based burgers on European menus this year

Business Times9 hours ago

IMPOSSIBLE FOODS hopes to add its plant-based burgers to European menus this year, bringing to a close a six-year quest to enter the world's biggest market for meat alternatives.
It would mark a major breakthrough for the Redwood City, California-based company as industry sales of plant-based meat substitutes shrink in its core American market.
Before rolling out all its products to countries including Germany, the Netherlands and the UK, the firm is still awaiting final regulatory approvals for its genetically-modified ingredient, according to chief executive officer Peter McGuinness.
Alternative proteins are a more environmentally friendly option to meat, but makers have been hit by consumer backlash against their taste, texture and concerns about ultraprocessed ingredients.
Meanwhile, demand for meat has been boosted by weight-loss drugs and a wave of Maga masculinity rhetoric. By contrast, European retailers are still rolling out plant-based ranges to consumers who care more about sustainability.
'Plant-based has more consumption in the EU and the UK than the US and people are generally more open to it,' McGuinness said in an interview in London. 'We're ready to go. We know it's going to get approved.'
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
Impossible Burger mimics the taste and texture of beef with plant-based ingredients. It contains soy leghemoglobin, an additive known as heme, which helps the product taste, smell and even 'bleed' like meat and is derived from a genetically-modified yeast strain.
The products are already available in countries including Australia, New Zealand and Canada, but Europe's strict regulations on novel ingredients and GM foods have slowed the approval process.
While the EU's food safety watchdog ruled late last year the ingredient didn't raise safety concerns, Impossible Foods is now awaiting the final nod from the European Union officials in the next few months.
It also has a pending risk assessment from the Food Standards Agency in the UK, which it hopes to obtain in late summer. There is a likelihood that the full approval may not come until next year, the company said.
Impossible Foods already offers a limited range of plant-based 'chicken' products, which don't contain heme.
The company has met with large UK retailers like Tesco, Waitrose and J Sainsbury and 'they all want our product because they want to expand their category,' he told the audience of the Bloomberg Sustainable Business Summit in London on Thursday.
'They're starting to see trends where the consumption's going down because the consumer wants better tasting food,' he said. 'So they would love our products here.'
McGuinness took over as the CEO in 2022 - switching from yogurt maker Chobani Inc - to oversee Impossible Foods' expansion into retailers and supermarkets in the US, which now make up about half of the business, he said.
But the US market has been shrinking, just as investor funding in alternative proteins has dried up and more startups are going out of business.
There are some 200 plant-based brands in the US, which is confusing to customers, McGuinness said. Impossible Foods has laid off workers over the past few years, as the value of the company's shares slumped.
McGuinness is dialing down on the climate, anti-cattle rhetoric, which he thinks alienated many people, led to politicising of the product, and contributed to mismarketing of the category in the beginning.
He's targeting meat eaters by emphasising the taste, protein content and nutrient-density of its products. His pitch includes changing the colour of packaging from green to red.
'This only works if we get meat eaters to come try the product,' he said. 'I know once I get them to try it, they actually like it.'
The repeat rate among customers - a gauge of whether consumers like a product - is 'a little bit over 50 per cent,' McGuinness said. Impossible is the fastest growing plant-based company in the world, he said.
Impossible Foods is expanding its distribution network to increase availability. While achieving price parity with conventionally produced meat will take longer, the company's products are now the same price or less expensive than organic, grass-fed beef, the CEO said.
'What's going to bring it to the next level is choice and taste,' McGuinness said. 'We've doubled down on taste and at the end of the day it's food.' BLOOMBERG

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CCCS okays Tamarind Health's proposed acquisition of TalkMed
CCCS okays Tamarind Health's proposed acquisition of TalkMed

Business Times

time42 minutes ago

  • Business Times

CCCS okays Tamarind Health's proposed acquisition of TalkMed

[SINGAPORE] The Competition and Consumer Commission of Singapore (CCCS) has cleared Tamarind Health's proposed acquisition of tertiary healthcare service provider TalkMed Group on Friday (Jun 27). The competition watchdog assessed that the proposed transaction will not substantially lessen competition within the Singapore market. TW Troy, a special purpose vehicle managed by Tamarind Health, proposed to privatise mainboard-listed TalkMed by way of scheme of arrangement, at S$0.456 per share, on Dec 23, 2024. CCCS said it commenced its review on Jan 13 to see whether the proposed privatisation would infringe Section 54 of the Competition Act 2004, which prohibits mergers that may substantially lessen competition. It conducted a public consultation from Jan 21 to 31, seeking feedback from stakeholders such as the involved parties' competitors and insurance service providers. Based on its assessment of the parties' submissions and third-party feedback, CCCS concluded that the proposed transaction is unlikely to substantially lessen competition in Singapore in relation to the supply of private medical oncology services. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Medical oncology refers to the field of medicine that deals with the treatment of cancer primarily with drugs, such as chemotherapy. CCCS reasoned that patients can choose alternative providers of medical oncology services in both public and private sectors in Singapore, limiting the impact of the proposed merger. Furthermore, it added that any increase in the parties' market power upon the proposed transaction would likely be constrained by insurers – who play a 'significant role' in affecting how patients select and finance private medical oncology services – as well as the regulatory framework governing the healthcare sector in Singapore. Tamarind is a pan-Asian oncology-focused group headquartered in Singapore. It is controlled by alternative asset manager Templewater and its affiliates. As part of the deal, 65 Equity Partners, a Singapore-based global investment firm backed by Temasek, will subscribe for shares in Tamarind Health through its local enterprise fund. After the transaction, 65 Equity Partners will hold about 18.3 per cent of the voting interest in Tamarind Health, while doctor shareholders will hold about 31.3 per cent. Shares of TalkMed closed flat at S$0.45 on Friday, before CCCS' announcement.

Market Focus Daily: Friday, June 27, 2025
Market Focus Daily: Friday, June 27, 2025

Business Times

timean hour ago

  • Business Times

Market Focus Daily: Friday, June 27, 2025

Japan's Nikkei ends at 6-month high, tracking Wall Street rally; Singapore's job vacancies, unemployment up in Q1, with US tariff impact yet to be seen; Info-Tech Systems launches IPO at S$0.87 apiece, marks SGX's first mainboard listing in two years; Japan's NTT files billion-dollar Reit listing with MAS; IPO set to be SGX's biggest in four years. Synopsis: Market Focus Daily is a closing bell roundup by The Business Times that looks at the day's market movements and news from Singapore and the region. Written and hosted by: Emily Liu (emilyliu@ Produced and edited by: Chai Pei Chieh & Claressa Monteiro Produced by: BT Podcasts, The Business Times, SPH Media --- BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Follow BT Market Focus and rate us on: Channel: Amazon: Apple Podcasts: Spotify: YouTube Music: Website: Feedback to: btpodcasts@ Do note: This podcast is meant to provide general information only. SPH Media accepts no liability for loss arising from any reliance on the podcast or use of third party's products and services. Please consult professional advisors for independent advice. Discover more BT podcast series: BT Money Hacks at: BT Correspondents: BT Podcasts: BT Branded Podcasts: BT Lens On:

Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility
Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility

Business Times

timean hour ago

  • Business Times

Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility

[SINGAPORE] Alcon, a Swiss-American pharmaceutical and medical device company specialising in eye care products, opened its expanded manufacturing and logistics facility in Tuas on Friday (Jun 27). This brings its total investment in Singapore to more than US$600 million since opening its first manufacturing site here in 2005. Located in Tuas Biomedical Park, the facility is one of Alcon's largest manufacturing sites, featuring advanced automation, smart manufacturing systems and industry 4.0 capabilities to support the increasing global demand for its contact lenses. It is also designed for operational efficiency and sustainability, with automation; digital systems; and features that reduce energy use, water consumption and waste. It has achieved zero waste to landfill and supports scalable production for global demand. Speaking at the launch event, Senior Minister of State for Trade and Industry Low Yen Ling said the partnership between Alcon and Singapore over the past 20 years exemplifies how deep, sustained collaboration can drive industrial growth and create meaningful careers for Singaporeans. 'Singapore is home to some of the world's best-in-class medtech manufacturing plants. The sector has been growing steadily, with a manufacturing output of S$19.4 billion in 2023, a nearly fourfold increase over the past decade,' she said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up In a statement, Alcon said that the expansion is expected to create new 'high-value' jobs in areas such as manufacturing, quality control and distribution management. It will also support Singapore's ambition to grow its medtech workforce, which comprises over 400 companies and employs more than 16,000 people as of 2024. The company partners with local institutions and workforce programmes to build skills in precision engineering, biomedical sciences and artificial intelligence automation, supporting the growth of Singapore's medtech sector. One initiative is the Career Conversion Programme (CCP), which allowed the firm to tap into a broader, more diverse talent pool, including mid-career switchers and individuals seeking new roles. To date, nearly 180 associates have benefited. Muhammad Haiqal Sapuan, a beneficiary of the programme, worked in the oil and gas sector previously and joined Alcon as a senior technician in 2022. After participating in the CCP and undergoing strong mentoring, he now serves as an associate supervisor, leading a team of 15 in production technical operations. Alcon currently employs more than 25,000 people worldwide and serves over 260 million patients across 140 countries annually.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store